Vaccine against acinetobacter baumannii based on cellular components deficient in lipopolysaccharide

Abstract

The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and/or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases produced by organisms of the genus Acinetobacter.

1 .- 17 . (canceled) 
     
     
         18 . A method of producing an antibody or fragment thereof that targets  Acinetobacter baumannii , comprising:
 a) contacting an antibody or fragment thereof or an antibody or antibody fragment library with an  A. baumannii  strain deficient in lipopolysaccharide (LPS) and/or an outer membrane vesicle (OMV) derived therefrom; and   b) selecting those antibodies or fragments thereof having affinity or binding affinity or capable of specifically binding the  A. baumannii  strain and/or OMV derived therefrom.   
     
     
         19 . The method of  claim 18 , further comprising isolating the antibody or fragment thereof identified in step b) above. 
     
     
         20 . The method of  claim 18 , wherein the antibody or fragment thereof is a Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′)2, Vhh, Nanobody, or diabody. 
     
     
         21 . The method of  claim 18 , wherein the  A. baumannii  strain deficient in LPS is characterized by the partial or complete inactivation of one or more genes selected from the group consisting of lpxA, lpxC, and lpxD. 
     
     
         22 . The method of  claim 18 , wherein the  A. baumannii  strain deficient in LPS is derived from ATCC strain 19606. 
     
     
         23 . The method of  claim 18 , wherein the  A. baumannii  strain deficient in LPS is an ATCC 19606 strain with a mutation in one or more genes selected from the group consisting of lpxA, lpxC and lpxD. 
     
     
         24 . A method of producing an antibody or fragment thereof that targets  Acinetobacter baumannii , comprising: administering an  A. baumannii  strain deficient in lipopolysaccharide (LPS) and/or an outer membrane vesicle (OMV) derived therefrom to a mammal. 
     
     
         25 . The method of  claim 24 , further comprising isolating the antibody or fragment thereof. 
     
     
         26 . The method of  claim 24 , wherein the antibody or fragment thereof is a Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , Vhh, Nanobody, or diabody. 
     
     
         27 . The method of  claim 24 , wherein the  A. baumannii  strain deficient in LPS is characterized by the partial or complete inactivation of one or more genes selected from the group consisting of lpxA, lpxC, and lpxD. 
     
     
         28 . The method of  claim 24 , wherein the  A. baumannii  strain deficient in LPS is derived from ATCC strain 19606. 
     
     
         29 . The method of  claim 24 , wherein the  A. baumannii  strain deficient in LPS is an ATCC 19606 strain with a mutation in one or more genes selected from the group consisting of lpxA, lpxC and lpxD.